Abstract
A salmon protein hydrolysate (SPH) was developed containing several angiotensin I-converting enzyme (ACE) inhibitory tripeptides the most abundant of which were Val-Leu-Trp, Val-Phe-Tyr, and Leu-Ala-Phe. Simulated digestion experiments showed that active constituents of SPH would survive in the digestive tract and be available for absorption into the bloodstream. In fact, ACE inhibitory activity was improved following simulated digestion suggesting that there were larger peptides in SPH that might contribute to bioactivity in vivo. A single oral dose (1,500 mg/kg body mass) of SPH significantly lowered blood pressure in spontaneously hypertensive rats (SHR). The treatment of SHR with either SPH fraction (<3,000 Da) or SPH fraction (>3,000 Da) reduced blood pressure. We conclude that the ability of SPH to lower blood pressure is due to a combination of ACE inhibitory tripeptides as identified, as well as additional unknown, peptide species that are generated during digestion of SPH in the gastrointestinal tract.
Similar content being viewed by others
References
Laragh JH, Bear L, Brunner HR et al (1972) Am J Med 52:633–652
Gavras H, Gavras I (1999) Biomed Health Res 22:41–50
Cushman DW, Ondetti MA, Gordon EM et al (1987) J Cardiovasc Pharmacol 10(Suppl 7):S17–S30
Fujita H, Yokoyama K, Yoshikawa M (2000) J Food Sci 65:564–569
Kawasaki T, Jun CJ, Fukushima Y et al (2002) Fukuoka Igaku Zasshi 93:208–218
Kim S-K, Byun H-G, Park P-J, Shahidi F (2001) J Agric Food Chem 49:2992–2997
Mizuno S, Matsuura K, Gotou T et al (2005) Br J Nutr 94:84–91
Mizushima S, Ohshige K, Watanabe J et al (2004) Am J Hypertens 17:701–706
Sato M, Oba T, Yamaguchi T et al (2002) Ann Nutr Metab 46:259–267
Seppo L, Jauhiainen T, Poussa T, Korpela R (2003) Am J Clin Nutr 77:326–330
Suetsuna K, Chen J-R (2001) Mar Biotechnol 3:305–309
Yokoyama K, Chiba H, Yoshikawa M (1992) Biosci Biotech Biochem 56:1541–1545
Fujita H, Yoshikawa M (1999) Immunopharmacology 44:123–127
Fujita H, Yamagami T, Ohshima K (2001) Nutr Res 21:1149–1158
Cushman DW, Cheung H-S (1971) Biochem Pharmacol 20:1637–1648
Holmquist B, Bunning P, Riordan JF (1979) Anal Biochem 95:540–548
Sato M, Takashi O, Yamaguchi T et al (2002) Ann Nutr Metab 46:259–267
Van Vliet BN, Chafe LL, Antic V, Schnyder-Candrian S, Montani JP (2000) J Pharmacol Toxicol Methods 44:361–373
Korhonen H, Pihlanto A (2003) Curr Pharm Design 9:1297–1308
Meisel H, FitzGerald RJ (2003) Curr Pharm Design 9:1289–1295
Vercruysse L, Van Camp J, Smagghe G (2005) J Agric Food Chem 53:8106–8115
Wu J, Aluko RE, Nakai S (2006) J Agric Food Chem 54:732–738
Fujita H, Yasumoto R, Hasegawa M, Ohsima K (1997) Jpn Pharmacol Ther 25:147–151
Kristinsson HG, Rasco BA (2002) Rec Adv Mar Biotechnol 7:157–182
Wu J, Aluko RE (2007) J Peptide Sci 13:63–69
Acknowledgments
Ocean Nutrition Canada (Private Company) and National Research Council of Canada-Industrial Research Assistance Program (NRC-IRAP).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ewart, H.S., Dennis, D., Potvin, M. et al. Development of a salmon protein hydrolysate that lowers blood pressure. Eur Food Res Technol 229, 561–569 (2009). https://doi.org/10.1007/s00217-009-1083-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00217-009-1083-3